Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint

Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint


The primary endpoint in CONCERTO -- the evaluation of laquinimod versus placebo to evaluate the time to Confirmed Disability Progression after at least 3 months - was not met. . Other data details announced by the Company show that on the secondary endpoint which measured change in brain volume-- an indicator of disability progression over time-- compared to baseline was positive .



from Biotech News